Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a Poorly Immunogenic Tumor Model

Cancer Immunology Research

Volumn 3, Issue 2, 2015, Pages 149-160

  Chen, Shihao ^a   Lee, Li Fen ^a   Fisher, Timothy S ^a   Jessen, Bart ^a   Elliott, Mark ^a   Evering, Winston ^a   Logronio, Kathryn ^a   Tu, Guang Huan ^a   Tsaparikos, Konstantinos ^a   Li, Xiaoai ^a   Wang, Hui ^a   Ying, Chi ^a   Xiong, Mengli ^a   Van Arsdale, Todd ^a   Lin, John C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 1BB ANTIBODY; ANTINEOPLASTIC AGENT; CD137 ANTIGEN; CD8ALPHA ANTIGEN; GAMMA INTERFERON; LAG 3 ANTIBODY; PD 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; CD223 ANTIGEN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL DIFFERENTIATION; COMPARATIVE STUDY; CYTOTOXICITY; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LIVER; MELANOMA, EXPERIMENTAL; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD137; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERFERON-GAMMA; LIVER; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 84934277025     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0118     Document Type: Article

References (45)

1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Ann Rev Med 2014;65:185-202.
4. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
5. Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009;229: 192-215.
6. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012;11:1062-70.
7. Wang S, Chen L. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Curr Topics Microbiol Immunol 2011; 344:245-67.
8. Vinay DS, Cha K, Kwon BS. Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med 2006;84:726-36.
9. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, et al. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 2013;210:743-55.
10. Kohrt HEK, Godwin JE, Lossos IS, Williams ME, Timmerman J, Link BK, et al. Aphase Ib, open-label, multicenter studyofurelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:abstr TPS3108.
11. Segal NH, Gopal AK, Bhatia S, Kohrt HE, Levy R, Pishvaian MJ, et al. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. J Clin Oncol 2014;32:abstr 3007.
12. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2:662-73.
13. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011;71:6567-71.
14. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72: 917-27.
15. Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med 2013;11:215.
16. Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother 2013;36:248-57.
17. Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS ONE 2013;8:e84927.
18. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013;73:6900-12.
19. Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006;66: 7276-84.
20. Jensen BA, Pedersen SR, Christensen JP, Thomsen AR. The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. PLoS ONE 2013;8:e66081.
21. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS ONE 2011;6:e19499.
22. Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, Tygrett LT, et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 2012;13:188-95.
23. Escuin-Ordinas H, Elliott M, Atefi M, Lee M, Ng C, Wei L, et al. PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. J Immuno Ther Cancer 2013;1:14.
24. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
25. Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, et al. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther 2012;20:1664-75.
26. + T-cell memory but not to effector differentiation. J Exp Med 2013; 210:1463-79.
27. Panteghini M, Bais R, vanSolinge WW. Enzymes. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics, 4th edn. St. Louis: Elsevier Saunders; 2006. p. 597-643.
28. Sharpe AH, Abbas AK. T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 2006;355:973-5.
29. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
30. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013;19:1044-53.
31. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014;124:687-95.
32. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591-603.
33. Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez Forero I, Labiano S, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013;19:6151-62.
34. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Seminars Oncol 2010;37:508-16.
35. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL. Multilayered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 2008;29:383-90.
36. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002;109:651-9.
37. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 2014;20:44-55.
38. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96.
39. + T cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005;6:1236-44.
40. Li G, Yang Q, Zhu Y, Wang HR, Chen X, Zhang X, et al. T-Bet and eomes regulate the balance between the effector/central memory T cells versus memory stem like T cells. PLoS ONE 2013;8:e67401.
41. + T cell function by the transcription factor Eomesodermin. Science 2003;302:1041-3.
42. Song C, Sadashivaiah K, Furusawa A, Davila E, Tamada K, Banerjee A. Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology 2014;3:e27680.
43. Wilcox RA, Flies DB, Wang H, Tamada K, Johnson AJ, Pease LR, et al. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. Cancer Res 2002;62:4413-8.
44. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, et al. Cytokinemediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007;178:4194-213.
45. Sznol M, Hodi FS, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 2008;26:3007.